Takeda Pharmaceutical Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Takeda Pharmaceutical is forecast to grow earnings and revenue by 11.8% and 0.8% per annum respectively. EPS is expected to grow by 11.8% per annum. Return on equity is forecast to be 4.1% in 3 years.
Anahtar bilgiler
11.8%
Kazanç büyüme oranı
11.8%
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 19.4% |
Gelir büyüme oranı | 0.8% |
Gelecekteki özkaynak getirisi | 4.1% |
Analist kapsamı | Good |
Son güncelleme | 02 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
3/31/2027 | 4,530,480 | 292,370 | 686,503 | 973,123 | 17 |
3/31/2026 | 4,461,038 | 229,800 | 695,167 | 950,866 | 18 |
3/31/2025 | 4,458,730 | 114,395 | 377,184 | 879,592 | 14 |
9/30/2024 | 4,546,083 | 289,996 | 536,390 | 876,306 | N/A |
6/30/2024 | 4,413,134 | 149,920 | 444,957 | 794,248 | N/A |
3/31/2024 | 4,263,762 | 144,067 | 235,614 | 716,344 | N/A |
12/31/2023 | 4,169,049 | 178,219 | -129,035 | 731,449 | N/A |
9/30/2023 | 4,154,414 | 191,626 | 129,243 | 963,227 | N/A |
6/30/2023 | 4,113,631 | 301,398 | 180,765 | 985,315 | N/A |
3/31/2023 | 4,027,478 | 317,017 | 343,467 | 977,156 | N/A |
12/31/2022 | 3,944,611 | 274,525 | 817,615 | 1,059,047 | N/A |
9/30/2022 | 3,749,354 | 213,167 | 789,089 | 1,028,328 | N/A |
6/30/2022 | 3,591,868 | 197,389 | 798,367 | 1,040,488 | N/A |
3/31/2022 | 3,569,006 | 230,059 | 937,068 | 1,123,105 | N/A |
12/31/2021 | 3,465,991 | 438,515 | 902,309 | 1,148,481 | N/A |
9/30/2021 | 3,401,450 | 473,105 | 777,572 | 1,018,931 | N/A |
6/30/2021 | 3,345,565 | 431,178 | 793,645 | 1,031,928 | N/A |
3/31/2021 | 3,197,812 | 376,005 | 774,463 | 1,010,931 | N/A |
12/31/2020 | 3,199,240 | 180,631 | 608,015 | 795,408 | N/A |
9/30/2020 | 3,221,804 | 56,051 | 498,511 | 720,676 | N/A |
6/30/2020 | 3,243,917 | 119,743 | 479,618 | 694,824 | N/A |
3/31/2020 | 3,291,188 | 44,241 | 452,042 | 669,752 | N/A |
12/31/2019 | 3,236,697 | 13,275 | 402,421 | 601,798 | N/A |
9/30/2019 | 2,876,782 | 83,262 | 399,600 | 551,732 | N/A |
6/30/2019 | 2,496,511 | 63,959 | 266,965 | 408,797 | N/A |
3/31/2019 | 2,097,224 | 135,192 | 194,365 | 328,479 | N/A |
12/31/2018 | 1,780,976 | 110,414 | 221,992 | 336,742 | N/A |
9/30/2018 | 1,769,726 | 140,738 | 225,190 | 328,658 | N/A |
6/30/2018 | 1,772,125 | 120,339 | N/A | 343,761 | N/A |
3/31/2018 | 1,770,531 | 186,886 | N/A | 377,854 | N/A |
12/31/2017 | 1,785,773 | 190,172 | N/A | 376,566 | N/A |
9/30/2017 | 1,762,667 | 163,457 | N/A | 316,619 | N/A |
6/30/2017 | 1,746,286 | 160,202 | N/A | 285,157 | N/A |
3/31/2017 | 1,732,051 | 114,940 | N/A | 261,363 | N/A |
12/31/2016 | 1,729,967 | 132,194 | N/A | -8,176 | N/A |
9/30/2016 | 1,754,130 | 150,081 | N/A | 42,293 | N/A |
6/30/2016 | 1,795,088 | 155,110 | N/A | 57,618 | N/A |
3/31/2016 | 1,807,378 | 80,166 | N/A | 25,491 | N/A |
12/31/2015 | 1,831,096 | -111,874 | N/A | 203,553 | N/A |
9/30/2015 | 1,830,521 | -152,827 | N/A | 192,836 | N/A |
6/30/2015 | 1,812,971 | -154,591 | N/A | 189,123 | N/A |
3/31/2015 | 1,777,824 | -145,775 | N/A | 182,517 | N/A |
12/31/2014 | 1,744,795 | 75,405 | N/A | N/A | N/A |
9/30/2014 | 1,714,694 | 103,390 | N/A | 240,094 | N/A |
6/30/2014 | 1,692,531 | 110,981 | N/A | N/A | N/A |
3/31/2014 | 1,691,685 | 106,658 | N/A | 148,335 | N/A |
12/31/2013 | 1,655,033 | 103,330 | N/A | N/A | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: TAKP34's forecast earnings growth (11.8% per year) is above the savings rate (10.1%).
Kazançlar ve Piyasa: TAKP34's earnings (11.8% per year) are forecast to grow slower than the BR market (13.1% per year).
Yüksek Büyüme Kazançları: TAKP34's earnings are forecast to grow, but not significantly.
Gelir ve Pazar: TAKP34's revenue (0.8% per year) is forecast to grow slower than the BR market (7.5% per year).
Yüksek Büyüme Geliri: TAKP34's revenue (0.8% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: TAKP34's Return on Equity is forecast to be low in 3 years time (4.1%).